Disease · MONDO_0018229

Stevens-Johnson syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Stevens-Johnson syndrome. Diseases, record MONDO_0018229. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018229

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Stevens-Johnson syndrome; Open Targets
Open Targets ID: MONDO_0018229; Open Targets
Other names: Dermatostomatitis, Stevens Johnson type; Open Targets
Disease Ontology: DOID:0050426; Disease Ontology
MeSH: D013262; MeSH
NCI Thesaurus: C79484; NCI Thesaurus
Orphanet: ORPHA:36426; Orphanet
Highest stage of its drugs: Approval, for 4 of its 10 drugs, from DailyMed; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	2	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 2/3	https://conductscience.org/library/genes/1441	Drugs and targets
JAK1	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Unknown	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Unknown	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Unknown	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Unknown	https://conductscience.org/library/genes/7297	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01276314	Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions	Not applicable	135	2017-12-19	Drug Hypersensitivity	PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT06474078	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN	Not applicable	20	2025-09-16	Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT04651439	Severe Bullous Drug Eruption and Filgrastim	Phase 2/3	42		Rare Diseases, Toxic Epidermal Necrolyses	FILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT02987257	NATIENS: Optimal Management and Mechanisms of SJS/TEN	Phase 3	2		Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT01256489	Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)	Phase 1/2	0		Stevens-Johnson Syndrome, Corneal Blindness	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02126020	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Phase 1/2	0		Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24928706	RESULT	1	PubMed
17919775	RESULT	1	PubMed
29400697	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018229

GET https://conductscience.org/api/diseases/v1/MONDO_0018229/drugs

API reference For AI assistants